Search

Displaying results 4691 - 4700 of 6949 in total
  1. Drug

    Faropenem

    go.drugbank.com/drugs/DB12190
    Investigational

    Faropenem has been used in trials studying the treatment of Tuberculosis, Pulmonary Tuberculosis, and Community Acquired Pneumonia.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Piboserod

    go.drugbank.com/drugs/DB04873
    Investigational

    Piboserod (SB 207266) is a selective 5-HT(4) receptor antagonist.

  3. Drug

    Remikiren

    go.drugbank.com/drugs/DB00212
    Experimental

    Remikiren is an orally active, high specificity renin inhibitor.

  4. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. … Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006.

  5. Drug

    Vibriolysin

    go.drugbank.com/drugs/DB05135
    Experimental

    It is a new agent for enzymatic debridement, shown to rapidly and thoroughly hydrolyze burn wound eschar within full-thickness wounds.

  6. Drug

    PX-478

    go.drugbank.com/drugs/DB06082
    Investigational

    PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical trial in patients with advanced metastatic cancer and lymphoma. PX-478 was effective in models of both non-small cell lung cancer and ...

  7. Drug

    Mizolastine

    go.drugbank.com/drugs/DB12523
    Approved

    Mizolastine is under investigation in clinical trial NCT01928316 (A Bioequivalence Study of Domestic (Made in China) and Imported Mizolastine Tablets in Healthy Volunteers).

    Categories: Antihistamines for Systemic Use
  8. Drug

    CVT-6883

    go.drugbank.com/drugs/DB05936
    Experimental

    CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation

    Categories: Adenosine A2 Receptor Antagonists
  9. Drug

    ARCoV

    go.drugbank.com/drugs/DB15855
    Experimental

    As of July 2020, the vaccine candidate is set for Phase 1 clinical trials to investigate for safety, tolerance, and immunogenicity (ChiCTR2000034112). … Manufactured as a liquid, ARCoV is thermostable at room temperature for at least 1 week.

  10. Drug

    Fludiazepam

    go.drugbank.com/drugs/DB01567
    IllicitInvestigational

    It is a scheduled drug in the U.S., but is approved for use in Japan.